Icad Inc Stock Price, News & Analysis

iCAD reported Q3 2024 financial results with total revenue of $4.2 million, up 4% year-over-year. Annual Recurring Revenue (ARR) reached $9.3 million, showing a 10% increase. The company achieved an 86% gross profit margin and closed 13 cloud deals, including partnerships with UCSD and Charlotte Radiology. Notable developments include FDA clearance of ProFound Detection v4.0, delivering 22% improvement in detecting challenging cancer subtypes and 18% reduction in false positives. The company reported a GAAP net loss of ($1.8) million or ($0.07) per share. Cash position stands at $18.8 million, which management believes is sufficient for planned operations.

iCAD announces FDA clearance for ProFound Detection Version 4.0, an AI-powered cancer detection solution for Digital Breast Tomosynthesis (DBT). The new version shows a 22% overall improvement in detecting challenging cancer subtypes, including a 50% improvement in dense breast tissue detection and 60% improvement in invasive lobular cancers identification. The solution features a 6.3% improved AUC over the previous version and introduces prior exam integration capability. The upgrade also delivers 18% improvement in reducing false positives, with 20% fewer vascular calcification marks and 51% fewer non-vascular calcification marks.

iCAD, a leader in AI-powered breast health solutions, announced its participation in the 15th Annual Craig-Hallum Alpha Select Conference on November 19, 2024, at the Sheraton New York Times Square Hotel. CEO Dana Brown and CFO Eric Lonnqvist will be available for one-on-one meetings during the event.

The conference serves as an idea generation platform for institutional investors, featuring over 90 selected companies with market caps under $500 million. Selected companies demonstrate characteristics such as attractive business models, strong management, competitive advantages, unique solutions, and growth prospects.

iCAD (NASDAQ: ICAD), a provider of AI-powered cancer detection solutions, has scheduled its Q3 2024 financial results release for November 13, 2024, after market close. The company will host a conference call at 4:30 PM Eastern Time on the same day. Investors can access the call via toll-free number 877-545-0320 or international number 973-528-0002 using participant code 509249. A webcast will also be available.

iCAD, a global leader in AI-powered breast health solutions, announced its participation in the LD Micro Main Event XVII on October 29-30, 2024, at the Luxe Sunset Boulevard Hotel, California. CEO Dana Brown will deliver a company presentation on Tuesday, October 29, at 10:30 a.m. PT / 1:30 p.m. ET and will be available for one-on-one meetings during the conference.

iCAD's mission is to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions. The company is listed on NASDAQ under the ticker symbol ICAD. Interested parties can register to watch the presentation virtually through the provided link.

iCAD announced its participation in the 72nd Journées Francophones de Radiologie (JFR) 2024 Meeting in Paris, highlighting the global availability of ProFound Cloud. This secure, scalable SaaS platform delivers iCAD's advanced AI solutions to healthcare providers worldwide, processing nearly 100,000 cases in its first two U.S. quarters with speeds over 50% faster than traditional on-premises solutions.

The company reported significant progress in global expansion, including new distribution partnerships in countries like Dominican Republic, France, Spain, Turkey, and UAE, as well as regulatory clearances in South Africa and UAE. Built on Google Cloud Platform, ProFound Cloud offers continuous updates and improved operational efficiency.

At JFR 2024, iCAD will host an AI Symposium led by Prof. Bruno Boyer, discussing the contribution of iCAD's AI solutions to breast cancer screening, detection, density evaluation, and risk assessment.

iCAD, a leader in AI-powered breast health solutions, announced its participation in the iAccess Alpha Buyside Best Ideas Fall Conference 2024. The event is scheduled for September 24-25, 2024. Key highlights include:

• CEO Dana Brown and CFO Eric Lonnqvist will deliver a company presentation on September 24 at 11:00 am ET.
• One-on-one meetings will be hosted on September 25.
• The presentation will be webcast live and available for replay.
• Interested parties can register and schedule meetings through the conference website.

This event provides an opportunity for investors to gain insights into iCAD's mission to create a world where cancer can't hide using clinically proven AI technology.

iCAD (NASDAQ: ICAD) reported strong financial results for Q2 2024. Total revenue increased by 21% to $5.0 million, driven by a 41.4% growth in product revenue. The company's gross profit margin improved to 84% from 81% in Q2 2023. GAAP Net loss from continuing operations decreased to ($1.7) million from ($2.3 million) in the same period last year.

Highlights include:
- Total ARR (Annual Recurring Revenue) reached $9.2 million, up 7% YoY
- 60 perpetual, 29 subscription, and 10 cloud deals closed in Q2
- ProFound Cloud SaaS platform launched successfully
- Cash and cash equivalents stood at $20.4 million as of June 30, 2024

iCAD's strategic focus on maximizing revenue from its install base and transitioning to cloud-based solutions appears to be yielding positive results.

iCAD Inc (NASDAQ: ICAD), a leader in AI-powered cancer detection solutions, has announced its plan to release Q2 2024 financial results on August 13, 2024, after market close. The company will host a conference call at 4:30 PM Eastern Time on the same day to discuss the results. Investors and analysts can access the call via toll-free number 888-506-0062 (US) or 973-528-0011 (International) using the participant access code 227167. A webcast of the earnings call will also be available for those who prefer to listen online.